The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections
Open accessAbstract
Studies of β-lactam pharmacodynamics in infected patients are sparse. In this study, classification and regression tree (CART) and logistic regression analyses were used to identify which pharmacodynamic indices and magnitudes were significant predictors of meropenem efficacy for 101 adult patients with lower respiratory tract infections (LRTI). Using demographic data, a validated population pharmacokinetic model was employed to predict pharmacokinetic parameters and free serum concentrations in the studied patients. Pharmacodynamic indices [percentage of the dosing interval that free drug concentrations remain above the MIC (%fT> MIC),f(maximum concentration of drug in serum) (fCmax)/MIC,fCmin/MIC, and f(area under the concentration-time curve) (f AUC)/MIC] were calculated based on the baseline pathogen with the highest drug MIC for each patient. The median (range) of percent fT> MIC,fCmax/MIC,fCmin/MIC, and f AUC/MIC were 100% (0 to 100%), 728.8 (0.8 to 15,777), 19.9 (0.01 to 278), and 3,605.4 (2.7 to 60,865.9), respectively. CART identified the following breakpoints as significant predictors for microbiological response: >54%fT> MIC, a fCmax/MIC > 383, and a fCmin/MIC > 5;fCmin/MIC > 5 was the only significant predictor of clinical response. Due to 100%fT> MIC achieved in the majority of LRTI patients,fCmin/MIC was the statistically significant parameter associated with meropenem clinical and microbiological response in the adults with LRTI. The findings for LRTI patients can be applied to optimize meropenem dose regimens to achieve clinical success and microbiological eradication in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacodynamics of β‐Lactams
Turnidge, J. D. (1998) · Clinical Infectious Diseases · doi:10.1086/514622 · Cited by 593
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Prevention of Resistance: A Goal for Dose Selection for Antimicrobial Agents
Drusano, G. L. (2003) · Clinical Infectious Diseases · doi:10.1086/344653 · Cited by 356
Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B., & Pierce, P. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2793-2797.2001 · Cited by 299
Mouton, J. W., & den Hollander, J. G. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.5.931 · Cited by 275
Pharmacodynamics of cefepime in patients with Gram-negative infections
Tam, V. H. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf130 · Cited by 262
Meropenem: A Review of its Antibacterial Activity, Pharmacokinetic Properties and Clinical Efficacy
Wiseman, L. R., Wagstaff, A. J., Brogden, R. N., & Bryson, H. M. (1995) · Drugs · doi:10.2165/00003495-199550010-00007 · Cited by 209
Tam, V. H., Schilling, A. N., Neshat, S., Poole, K., Melnick, D. A., & Coyle, E. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.4920-4927.2005 · Cited by 196
Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia
Ariano, R. E., Nyhlén, A., Donnelly, J. P., Sitar, D. S., Harding, G. K., & Zelenitsky, S. A. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e271 · Cited by 185
Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients
Li, C., Kuti, J. L., Nightingale, C. H., & Nicolau, D. P. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291035 · Cited by 171
Self-citation
Cited by
Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Self-citationGuilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543
Roberts, J. A., Abdul-Aziz, M.-H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0024oc · Cited by 379
Metadata
- Authors
- Li, C., Du, X., Kuti, J. L., & Nicolau, D. P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-05
- Volume
- 51
- Issue
- 5
- Pages
- 1725-1730
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2165839757
- Cited by
- 289
- References
- 14
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections. https://app.cochat.ai/papers/10.1128/aac.00294-06
- The paper
- Li, C., Du, X., Kuti, J. L., & Nicolau, D. P. (2007). Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00294-06
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.